03th Jan，2020 — Can-Fite BioPharma Ltd. issued an announcement, which is summarized as follows:
Can-Fite BioPharma Ltd. announced today that pre-clinical data generated at the Hadassah Medical Center by Dr. Rifaat Safadi’s lab demonstrate that Namodenoson induces weight loss in experimental models and normalizes glucose levels.
Dr. Safadi commented, “This new weight loss data, together with the good safety profile of Namodenoson, supports its potential utilization as an anti-obesity drug.”
Can-Fite completed enrollment in its Phase II study of Namodenoson in patients with NAFLD with or without NASH, with evidence of active inflammation. The primary endpoint of the study is serum ALT levels, with a secondary endpoint of percentage change in liver fat, as measured by PDFF (proton density fat fraction).
The Company expects to release data from the Phase II NAFLD/NASH study of Namodenoson during the first quarter of 2020.
The original website link: